vTv Therapeutics (NASDAQ:VTVT – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.97) per share and revenue of $0.3330 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. On average, analysts expect vTv Therapeutics to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
vTv Therapeutics Stock Performance
Shares of NASDAQ VTVT traded up $0.17 during mid-day trading on Tuesday, reaching $32.56. 30,495 shares of the company’s stock were exchanged, compared to its average volume of 53,919. The firm has a market capitalization of $128.29 million, a price-to-earnings ratio of -35.02 and a beta of 0.29. The company’s 50-day moving average is $33.35 and its 200-day moving average is $34.88. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00.
Hedge Funds Weigh In On vTv Therapeutics
Analysts Set New Price Targets
VTVT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Zacks Research downgraded vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Finally, BTIG Research raised their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, vTv Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.67.
Check Out Our Latest Analysis on vTv Therapeutics
vTv Therapeutics Company Profile
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.
Read More
- Five stocks we like better than vTv Therapeutics
- Apple’s AI Strategy Looks Different—Will It Pay Off?
- The AI Chip Stock Making a Quiet Move Toward Dominance
- Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
- Dodging Deutsche Telekom: T-Mobile’s Strategic Win
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
